Flatiron Health and Massive Bio Partner to Improve Clinical Trial Enrollment

What You Should Know: 

– Flatiron Health, a healthtech company focused on transforming clinical research through technology that integrates research into everyday care, has announced a strategic partnership with Massive Bio, a global leader in using artificial intelligence to streamline patient identification and recruitment for clinical trials.

– The partnership aims to expand patient identification capabilities and improve clinical trial enrollment across the U.S. 

Enhance Patient Identification Capabilities and Services

This collaboration will utilize Massive Bio’s U.S.-based database to identify patients who may be eligible for clinical trials but are not currently enrolled and are located near participating trial sites. These patients will then be referred to Flatiron’s research sites, where they can be onboarded as new patients and evaluated for potential trial enrollment using Flatiron’s technology and centralized patient identification services.

“At Massive Bio, our mission is to make access to clinical trials truly patient-centric, ensuring the right patient is matched to the right trial at the right time—no matter where they live,” said Dr. Arturo Loaiza-Bonilla, Co-Founder and Chief Medical Officer at Massive Bio. “By pairing our AI-driven platform and concierge services with Flatiron Health’s extensive research infrastructure, we can help physicians and care teams expedite trial enrollment, reduce disparities in access, and improve outcomes for more patients.”